Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Cerliponase alfa is a purified human enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. The active substance is a recombinant human tripeptidyl peptidase-1 (rhTPP1), a lysosomal exopeptidase. The primary activity of the mature enzyme is the cleavage of N-terminal tripeptides from a broad range of protein substrates.
Cerliponase alfa contains 544 amino acids with an average molecular mass of 59 kDa. The mature enzyme is 368 amino acids in length. There are 5 consensus N-glycosylation sites on rhTPP1 that contain high mannose, phosphorylated high mannose and complex glycosylation structures.
Brineura (cerliponase alfa) Injection and Intraventricular Electrolytes Injection are administered by intraventricular infusion. The solutions are sterile, nonpyrogenic, and free of foreign particulates. Brineura is a clear to slightly opalescent and colorless to pale yellow solution. Intraventricular Electrolytes is a clear to colorless solution.
Brineura and Intraventricular Electrolytes Injection are packaged in 10 mL clear Type 1 single-dose glass vials [see HOW SUPPLIED]. Each vial of Brineura provides 5 mL of solution containing 150 mg cerliponase alfa. Each vial of Intraventricular Electrolytes Injection provides 5 mL of solution. Both Brineura and Intraventricular Electrolytes Injection are formulated with the following excipients: calcium chloride dihydrate (1.05 mg); magnesium chloride hexahydrate (0.8 mg); potassium chloride (1.1 mg); sodium chloride (43.85 mg); sodium phosphate, dibasic, heptahydrate (0.55 mg); sodium phosphate, monobasic, monohydrate (0.4 mg); and Water for Injection, USP. The pH of the solution is between 6.2 to 6.8 for Brineura, and between 6.0 to 7.0 for Intraventricular Electrolytes Injection.
Each vial contains: sodium: 0.76 mEq, and potassium: 0.015 mEq.
BRINEURA is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
The recommended dosage of BRINEURA in pediatric patients is provided in Table 1. The dose is administered once every other week by intraventricular infusion.
BRINEURA is not recommended in patients less than 37 weeks post-menstrual age (gestational age at birth plus post-natal age) or those weighing less than 2.5 kg [see Use In Specific Populations].
Administer BRINEURA first followed by infusion of the Intraventricular Electrolytes. The complete BRINEURA infusion, including the required infusion of Intraventricular Electrolytes, is approximately 2 to 4.5 hours, depending on the dose and volume administered. See Table 1 for the appropriate volume and infusion rate. For volumes that are not whole numbers, see Administration Instructions For Intraventricular Infusion.
Table 1: BRINEURA Dose, Volume, and Infusion Rate by Age
| Age groups | BRINEURA dose administered every other week | Volume of BRINEURA solution | Infusion rate |
| Birth to < 6 months | 100 mg | 3.3 mL | 1.25 mL/hr |
| 6 months to < 1 year | 150 mg | 5 mL | 2.5 mL/hr |
| 1 year to < 2 years | 200 mg (first 4 doses) 300 mg (subsequent doses) |
6.7 mL (first 4 doses) 10 mL (subsequent doses) |
2.5 mL/hr |
| 2 years and older | 300 mg | 10 mL | 2.5 mL/hr |
If one or more doses are missed, restart BRINEURA treatment as soon as possible, maintaining the 2-week interval between infusions thereafter.
In the event of a severe hypersensitivity reaction (e.g., anaphylaxis), immediately discontinue BRINEURA administration and initiate appropriate medical treatment. If the decision is made to readminister BRINEURA after the occurrence of anaphylaxis, initiate the subsequent infusion at approximately one-half the infusion rate at which the anaphylactic reaction occurred with appropriate premedication. For additional recommendations in the event of a hypersensitivity reaction, see WARNINGS AND PRECAUTIONS.
BRINEURA and the Intraventricular Electrolytes must only be administered by the intraventricular route, using the provided Administration Kit for use with BRINEURA. Each vial of BRINEURA and Intraventricular Electrolytes is intended for a single dose only.
BRINEURA is administered into the cerebrospinal fluid (CSF) by infusion via a surgically implanted reservoir and catheter (the “intraventricular access device system”). BRINEURA is intended to be administered via the Codman® HOLTER RICKHAM Reservoirs (Part Numbers: 82-1625, 82-1621, 82-1616) with the Codman® Ventricular Catheter (Part Number: 82-1650). The intraventricular access device reservoir and catheter must be implanted prior to the first infusion. It is recommended that the first dose be administered at least 5 to 7 days after device implantation.
BRINEURA is intended to be administered with the B Braun Perfusor® Space Infusion Pump System (Product Code: 8713030U). If an alternative pump must be used, the essential performance requirements for this syringe pump used to deliver BRINEURA are as follows:
Administer BRINEURA and the Intraventricular Electrolytes using the provided Administration Kit for use with BRINEURA components [see HOW SUPPLIED].
Each infusion consists of 3.3 to 10 mL of BRINEURA followed by 2 mL of Intraventricular Electrolytes. The complete infusion must be administered using an infusion set with a 0.2 micron inline filter. The Intraventricular Electrolytes are used to flush the infusion line, port needle, and intraventricular access device in order to fully administer BRINEURA and to maintain patency of the intraventricular access device.
Supplies for Infusion Preparation
Inspect the Administration Kit infusion components to ensure the components are in the individual packages and have not been compromised.
Thaw BRINEURA and Intraventricular Electrolytes Injection vials at room temperature 20°C to 25°C (68°F to 77°F) for approximately 60 minutes. Do not thaw or warm vials any other way. Do not shake vials. Condensation will occur during thawing period. Do not re-freeze vials or freeze syringes containing BRINEURA or Intraventricular Electrolytes.
Inspect fully thawed BRINEURA and Intraventricular Electrolytes Injection vials. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. BRINEURA is a clear to slightly opalescent and colorless to pale yellow solution. Intraventricular Electrolytes is a clear to colorless solution. Do not use if the solutions are discolored or if there is other foreign particulate matter in the solutions. BRINEURA vials may occasionally contain thin translucent fibers or opaque particles. These naturally occurring particles are cerliponase alfa. These particles are removed via the 0.2 micron inline filter without having a detectable effect on the purity or strength of BRINEURA. Intraventricular Electrolytes may contain particles, which appear during the thaw period; however, these dissolve when the solution reaches room temperature.
Use thawed BRINEURA and Intraventricular Electrolytes immediately. If thawed BRINEURA and Intraventricular Electrolytes is not used immediately, store in the refrigerator at 2°C to 8°C (36°F to 46°F) for no more than 24 hours. Discard the thawed product after 24 hours if refrigerated.
Use product held in labeled syringes immediately. If product held in labeled syringe is not used immediately, store in the refrigerator at 2°C to 8°C (36°F to 46°F) for no more than 4 hours prior to infusion. Discard the product held in labeled syringe after 4 hours if refrigerated.
Figure 1 represents the intraventricular infusion system set up. Use aseptic technique during the infusion. Follow the steps below to proceed with the intraventricular infusion.
 |
 |
 |
 |
 |
Administer the Intraventricular Electrolytes provided after BRINEURA infusion is complete.
 |
Dispose of the infusion components, needles, unused solutions and other waste materials in accordance with local requirements.
Injection: BRINEURA 150 mg/5 mL (30 mg/mL) solution, two single-dose vials per carton co-packaged with Intraventricular Electrolytes Injection 5 mL in a single-dose vial. BRINEURA is a clear to slightly opalescent and colorless to pale yellow solution. Intraventricular Electrolytes is a clear to colorless solution [see HOW SUPPLIED].
BRINEURA is supplied as a sterile, clear to slightly opalescent and colorless to pale yellow solution for intraventricular infusion and Intraventricular Electrolytes Injection is supplied as a clear to colorless solution for intraventricular infusion; both are included in package 1 of 2. The Administration Kit for use with BRINEURA is supplied separately as package 2 of 2 [see DOSAGE AND ADMINISTRATION].
Each BRINEURA (cerliponase alfa) Injection vial has a green flip-off cap (plastic) and contains 150 mg cerliponase alfa per 5 mL (30 mg/mL).
Each Intraventricular Electrolytes Injection vial has a yellow flip-off cap (plastic) and contains 5 mL of solution.
| Contents of Package 1 | NDC Number |
| BRINEURA (cerliponase alfa) Injection (2 vials of 150 mg/5 mL) Intraventricular Electrolytes Injection (1 vial, 5 mL) |
68135-811-02 |
The Administration Kit for use with BRINEURA is supplied separately and contains the following single-use, sterile infusion components:
BRINEURA (cerliponase alfa) Injection and Intraventricular Electrolytes Injection: Store upright in a freezer (-25°C to -15°C) in original carton to protect from light.
Administration Kit for use with BRINEURA:
Store in original carton separately from BRINEURA. Do not freeze.
Manufactured by: BioMarin Pharmaceutical Inc. Novato, CA 94949. Revised Jul 2024.
The following adverse reactions are described below and elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of BRINEURA was evaluated in 24 patients with CLN2 disease who received at least one 300 mg dose of BRINEURA given by intraventricular infusion in a clinical trial with extension (Trials 1 and 2) of up to 161 weeks [see Clinical Studies]. Table 2 summarizes the most common adverse reactions that occurred in BRINEURA-treated patients through 96 weeks.
Table 2: Adverse Reactions Reported in ≥ 8% of Symptomatic Pediatric Patients with CLN2 Disease in BRINEURA Trial 1 and Trial 2 at Week 96
| Adverse Reaction | Patients Treated with |
| BRINEURA | |
| n=24 (%) | |
| Increased body temperature1 | 17 (71) |
| ECG abnormalities2 | 17 (71) |
| Decreased CSF protein | 17 (71) |
| Vomiting | 15 (63) |
| Seizures3 | 12 (50) |
| Device-related complications4 | 12 (50) |
| Hypersensitivity5 | 9 (38) |
| Increased CSF protein | 5 (21) |
| Hematoma | 5 (21) |
| Headache | 4 (17) |
| Irritability | 4 (17) |
| Pleocytosis | 4 (17) |
| Device-related infections6 | 2 (8) |
| Bradycardia | 2 (8) |
| Feeling jittery | 2 (8) |
| Hypotension | 2 (8) |
| 1 Increased body temperature includes: increased body temperature and pyrexia 2 ECG abnormalities include: non-specific repolarization abnormality, notched QRS, ST segment elevation, biphasic T wave abnormality, supraventricular extrasystoles, bradycardia, sinus tachycardia, and intraventricular conduction delay 3 Seizures include: atonic, generalized tonic-clonic, focal, and absence 4 Device-related complications include device-related infection, delivery system-related complications (needle issues, device leakage, device malfunction, device difficult to use, medical device site irritation, device breakage, etc.) and pleocytosis. 5 Hypersensitivity includes only hypersensitivity [see WARNINGS AND PRECAUTIONS] 6 Device-related infections include: Propionibacterium acnes and Staphylococcus epidermidis |
|
Seizures were reported in 12 of 24 (50%) patients. The seizure types reported include atonic, generalized tonic-clonic, focal, and absence. Seizures were managed with standard anti-convulsive therapies and did not result in discontinuation of BRINEURA treatment.
Adverse reactions related to the device were observed in 12 of 24 (50%) of patients. Device-related adverse reactions include infection, delivery system-related complications, and pleocytosis. Nine out of 24 patients (38%) experienced adverse reactions, which involved complications of the non-implanted delivery system components. Four out of 24 patients (16%) had device-related adverse reactions, which required medical intervention, including two patients (8%) with intraventricular access device-related CNS infections, and one patient (4%) each with leakage of the intraventricular access device and pleocytosis. Device-related infections were diagnosed by increased CSF pleocytosis and microbiology culture and organism identification, without accompanying signs and symptoms of meningitis. Intraventricular access devices were replaced and infections were treated with antibiotics. Device-related complications did not result in discontinuation of BRINEURA treatment.
Hematoma adverse reactions were reported in 5 of 24 (21%) patients treated with BRINEURA and presented as hematoma, post procedural hematoma, traumatic hematoma and subdural hematoma. Hematomas did not require treatment and did not interfere with BRINEURA infusion.
Hypersensitivity reactions were reported in 11 out of 24 patients (46%) treated with BRINEURA during or within 24 hours after completion of the BRINEURA infusion, despite pre-medication with antihistamines with or without antipyretics or corticosteroids. The most common manifestations observed concomitantly with hypersensitivity included pyrexia with vomiting, pleocytosis, or irritability, which are not consistent with classic immune mediated hypersensitivity. Symptoms resolved over time or with administration of antipyretics, antihistamines and/or corticosteroids and no patient discontinued treatment with BRINEURA.
One patient experienced hypoxia (decreased oxygen saturation less than 88% by pulse oximeter), 8 hours after BRINEURA infusion, followed by a low mean arterial pressure at 15 hours post infusion. Symptoms resolved after oxygen administration, airway repositioning and normal saline infusion. One patient reported decreased oxygen saturation (90% by pulse oximeter), 45 minutes after starting BRINEURA with associated low diastolic blood pressures. Hypoxia resolved after oxygen administration. No treatment was administered for the low diastolic blood pressure, which returned to normal while the patient continued to receive BRINEURA infusion without change to the infusion rate or dose.
Trial 3 enrolled 14 patients aged 1 to 6 years at baseline who received BRINEURA at the recommended dose based on the age of the patient, every other week for a median of 142 weeks. Adverse reactions that occurred in at least 5% of patients are described in Table 3.
The most frequent adverse reactions reported in patients < 3 years treated with BRINEURA were similar to those observed in patients ≥ 3 years of age except for hypersensitivity reactions, which were reported in 5 of 8 (63%) in patients < 3 years at baseline compared with 0 of 6 in patients ≥ 3 years of age at baseline. The most common manifestations of hypersensitivity were pyrexia and vomiting and the timing and resolution were similar to Trials 1 and 2. Symptoms of severe hypersensitivity reactions (e.g., anaphylaxis) included tachycardia, bronchospasm, rash, diarrhea, hypotension, increased body temperature and vomiting.
In Trial 3, 12 patients (86%) who received BRINEURA had 83 IARs. Of those, 8 patients were < 3 years of age and 4 were ≥ 3 years of age. The symptoms occurring in more than one patient consisted of vomiting, seizure, rash, pyrexia, hypersensitivity, and abnormal electrocardiogram. Eight (57%) patients had serious IARs: pyrexia, hypersensitivity, anaphylactic reaction, seizure, and pleocytosis.
In Trial 3, 3 patients (21%) who received BRINEURA had 3 IARs related to the intraventricular device. Of those, 2 were < 3 years of age and 1 was ≥ 3 years of age. The events were: device leakage, device breakage, and CSF red blood cell count positive. One (7%) patient had a serious IAR of device leakage.
Table 3: Adverse Reactions Reported in ≥ 5% of Pediatric Patients (1 to 6 years of age) with CLN2 Disease treated with BRINEURA in Trial 3
| Adverse Reaction | Age 1 to 3 years n=8 (%) |
Age 3 to 6 years n=6 (%) |
Total n=14 (%) |
| ECG abnormalities1 | 8 (100) | 6 (100) | 14 (100) |
| Decreased CSF protein | 8 (100) | 4 (67) | 12 (86) |
| Increased body temperature2 | 6 (75) | 6 (100) | 12 (86) |
| Seizures3 | 4 (50) | 4 (67) | 8 (57) |
| Device-related complications4 | 3 (36) | 2 (33) | 5 (36) |
| Vomiting | 2 (25) | 3 (50) | 5 (36) |
| Hypersensitivity5 | 4 (50) | 0 | 4 (29) |
| Hematoma | 2 (25) | 0 | 2 (14) |
| Increased CSF protein | 1 (13) | 0 | 1 (7) |
| Pleocytosis | 1 (13) | 0 | 1 (7) |
| Irritability | 0 | 1 (17) | 1 (7) |
| Headache | 1 (13) | 0 | 1 (7) |
| Note: Incidence numbers are based on baseline age group 1 ECG abnormalities include: non-specific repolarization abnormality, supraventricular extrasystoles, possible left ventricular hypertrophy, intermittent 2nd degree AV Block (type 2 Mobitz), incomplete right bundle branch block, and prominent Q wave. 2 Increased body temperature includes: increased body temperature and pyrexia. 3 Seizures include: atonic, febrile convulsion, generalized tonic-clonic, partial, partial with secondary generalization, petit mal epilepsy, myoclonic and status epilepticus. 4 Device-related complications include device-related infection, delivery system-related complications (needle issues, device leakage, device malfunction, device difficult to use, medical device site irritation, device breakage, etc.) 5 Hypersensitivity includes only the term of hypersensitivity |
|||
The following adverse reactions have been identified during post-approval use of BRINEURA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
No Information Provided
Included as part of the "PRECAUTIONS" Section
Life-threatening hypersensitivity reactions including anaphylaxis have been reported in patients treated with enzyme replacement therapies, including BRINEURA. BRINEURA-treated patients have had these reactions occur in clinical studies and postmarketing use [see ADVERSE REACTIONS]. In clinical Trial 1 and Trial 2 to 96 weeks, a total of 11 of 24 (46%) patients experienced hypersensitivity reactions during the infusion or within 24 hours of completion of the infusion. Patients in clinical trials were routinely premedicated with antihistamines with or without antipyretics or corticosteroids, prior to infusion of BRINEURA. During postmarketing use, anaphylactic reactions occurred during or within several hours of BRINEURA infusion. Epinephrine was administered in these patients, and they received subsequent BRINEURA infusions without recurrence of anaphylaxis.
In Trial 3, hypersensitivity reactions were reported in 5 of 8 (63 %) patients less than 3 years of age at baseline as compared to 0 of 6 patients ≥ 3 years of age at baseline [see ADVERSE REACTIONS]. Of the reported hypersensitivity reactions, a single anaphylactic reaction occurred in a subject < 3 years of age.
Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Administration of BRINEURA should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis. Initiate BRINERUA in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. Premedication of patients with antihistamines with or without antipyretics or corticosteroids is recommended 30 to 60 minutes prior to the start of infusion. Observe patients closely during and after the infusion. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue BRINEURA and immediately initiate appropriate medical treatment including use of epinephrine. Inform patients and caregivers of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur.
The management of hypersensitivity reactions should be based on the severity of the reaction and may include temporarily interrupting the infusion, and/or treatment with antihistamines, antipyretics, and/or corticosteroids. Consider the risks and benefits of readministration of BRINEURA following an anaphylactic reaction. If the decision is made to readminister BRINEURA after the occurrence of anaphylaxis, ensure appropriately trained personnel and equipment for emergency resuscitation (including epinephrine and other emergency medicines) are readily available during infusion. Initiate subsequent infusion at approximately one-half the initial infusion rate at which the anaphylactic reaction occurred.
Bacterial meningitis requiring antibiotic treatment and removal of the device was reported during postmarketing use of BRINEURA. Additionally, in clinical trials and during postmarketing use there were reports of other device-related clinical infections which were confirmed by positive CSF cultures, treated with antibiotics and removal of the entire intraventricular access device, and in which patients resumed treatment with BRINEURA after the device was replaced [see ADVERSE REACTIONS]. In all cases, antibiotics were administered, the intraventricular access devices were removed and replaced, and patients resumed treatment with BRINEURA.
The signs and symptoms of infections may not be readily apparent in patients with CLN2 disease. To reduce the risk of infectious complications, BRINEURA should be administered by, or under the supervision of, a physician experienced in intraventricular administration. Prior to each infusion of BRINEURA and when clinically indicated, obtain a sample of CSF for cell count and culture. Do not administer BRINEURA if there are localized signs of infection on or around the device insertion site, such as erythema, tenderness, or discharge or suspected or confirmed CNS infection (e.g., cloudy CSF or positive CSF gram stain, or meningitis) [see CONTRAINDICATIONS].
Healthcare providers should be vigilant for the development of signs and symptoms of infection, including meningitis, during treatment with BRINEURA and monitor the device insertion site for signs of infection.
During the clinical trials and in postmarketing reports, intraventricular access device-related complications were reported (e.g., device leakage, device failure extravasation of CSF fluid, or bulging of the scalp around or above the intraventricular access device) [see ADVERSE REACTIONS]. For any complications with the implanted intraventricular access device, consult with a neurosurgeon to confirm the integrity or performance of the device. In case of intraventricular access device-related complications, discontinue the BRINEURA infusion and refer to the device manufacturer’s labeling for further instructions [see CONTRAINDICATIONS].
Material degradation of the intraventricular access device reservoir was reported after approximately 4 years of administration, which may impact the effective and safe use of the device. During benchtop testing such material degradation was recognized after approximately 105 perforations of the intraventricular access device. The intraventricular access device should be replaced prior to 4 years of single-puncture administrations, which equates to approximately 105 administrations of BRINEURA.
Monitor vital signs (blood pressure, heart rate) before infusion starts, periodically during infusion, and post-infusion in a healthcare setting [see DOSAGE AND ADMINISTRATION]. Upon completion of the infusion, clinically assess the patient status. Continued observation may be necessary if clinically indicated.
Perform electrocardiogram (ECG) monitoring during infusion in patients with a history of bradycardia, conduction disorder, or with structural heart disease, as some patients with CLN2 disease may develop conduction disorders or heart disease. In patients without cardiac abnormalities, regular 12-lead ECG evaluations should be performed every 6 months.
In clinical Trial 1 and Trial 2 to 96 weeks, hypotension was reported in 2 of 24 (8%) patients, which occurred during or up to eight hours after BRINEURA infusion. Patients did not require alteration in treatment, and reactions resolved spontaneously or after intravenous fluid administration [see ADVERSE REACTIONS].
Infusion-associated reactions (IARs) such as vomiting, seizure, rash, pyrexia, hypersensitivity, and anaphylactic reaction have been observed in patients treated with BRINEURA [see ADVERSE REACTIONS].
Premedication of patients with antihistamines with or without antipyretics or corticosteroids is recommended 30 to 60 minutes prior to the start of infusion. If an IAR occurs, decreasing the infusion rate, temporarily stopping the infusion, and/or administering antihistamines and/or antipyretics may ameliorate the symptoms. Closely monitor patients who have experienced IARs when re-administering BRINEURA.
In Trial 3, infusion-associated reactions were reported in 8 of 8 patients less than 3 years of age at baseline as compared to 4 of 6 patients ≥ 3 years of age at baseline.
Carcinogenicity, genotoxicity, and fertility studies have not been performed with cerliponase alfa. Based on the mechanism of action, cerliponase alfa is not expected to be tumorigenic.
There are no available data on BRINEURA use in pregnant women to inform a drug-associated risk of pregnancy-related outcomes. Animal reproduction studies have not been conducted using cerliponase alfa.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
There are no data on the presence of cerliponase alfa in human milk, the effects on the breastfed child, or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of BRINEURA to an infant during lactation; therefore, the development and health benefits of breastfeeding should be considered along with the mother’s clinical need for BRINEURA and any potential adverse effects on the breastfed infant from BRINEURA or from the underlying maternal condition.
The safety and effectiveness of BRINEURA have been established to slow the loss of ambulation in pediatric patients with CLN2 disease and the information on this use is discussed throughout the labeling.
BRINEURA is not recommended for use in patients less than 37 weeks post-menstrual age (gestational age at birth plus post-natal age) or those weighing less than 2.5 kg due to physiologic immaturity which may increase risk of serious and clinically significant adverse reactions observed with BRINEURA [see WARNINGS AND PRECAUTIONS].
Patients less than 3 years of age may be at increased risk for developing hypersensitivity reactions with BRINEURA use compared to patients 3 years of age and older [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
No Information Provided
BRINEURA is contraindicated in patients with:
CLN2 disease is a neurodegenerative disease caused by deficiency of the lysosomal enzyme tripeptidyl peptidase-1 (TPP1), which catabolizes polypeptides in the CNS. TPP1 has no known substrate specificity. Deficiency in TPP1 activity results in the accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system (CNS), leading to progressive decline in motor function.
Cerliponase alfa (rhTTP1), a proenzyme, is taken up by target cells in the CNS and is translocated to the lysosomes through the Cation Independent Mannose-6-Phosphate Receptor (CI-MPR, also known as M6P/IGF2 receptor). Cerliponase alfa is activated in the lysosome and the activated proteolytic form of rhTPP1 cleaves tripeptides from the N-terminus of proteins.
No formal pharmacodynamic studies have been conducted with cerliponase alfa.
The pharmacokinetics of cerliponase alfa were evaluated in patients with CLN2 disease who received intraventricular infusions of 30 mg (0.1 times the maximum approved recommended dosage), 100 mg (approximately 0.3 times the maximum approved recommended dosage), and 300 mg over approximately 4.5 hours once every other week.
Cerliponase alfa CSF exposure following the initial single dose administration of BRINEURA increased less than proportionally across doses of 30 mg, 100 mg, and 300 mg. There was no apparent accumulation of cerliponase alfa in CSF or plasma when BRINEURA was administered at a dose of 300 mg once every other week.
Cerliponase alfa pharmacokinetics have high inter-subject and intra-subject variability. Following intraventricular infusions of 300 mg of BRINEURA at Day 1, Week 5, and Week 13, the pharmacokinetic parameters in CSF and plasma were assessed in 14 patients and are summarized in Table 4.
Table 4: Pharmacokinetic Parameters of Cerliponase Alfa Following Intraventricular Infusion (approximately 4.5 hours in duration) of BRINEURA 300 mg Every Two Weeks in Patients ≥ 3 years
| Parameter | Median [Min, Max] | |||
| Day 1 | Week 5 | Week 13 | ||
| CSF | N | 13 | 14 | 13 |
| Tmax1, hr | 4.5 [4.3, 5.8] | 4.3 [3.8, 4.5] | 4.3 [4.0, 4.5] | |
| Cmax, mcg/mL | 1260 [359, 4380] | 1630 [376, 4670] | 1390 [1110, 2340] | |
| AUC0-t, mcg-hr/mL | 9290 [3660, 19000] | 12400 [4620, 26200] | 10500 [7000, 18200] | |
| Vss, mL | 245 [78.4, 909] | 196 [85.4, 665] | 186 [131, 257] | |
| CL, mL/hr | 32.3 [15.8, 81.9] | 24.2 [11.4, 64.9] | 28.7 [16.5, 42.9] | |
| t1/2, hr | 6.2 [5.5, 16.3] | 7.4 [3.3, 9.5] | 7.7 [5.1, 9.4] | |
| Plasma2 | N | 12 | 12 | 9 |
| Tmax1, hr | 12.0 [4.3, 24.5] | 12.0 [7.5, 24.2] | 12.3 [4.3, 75.9] | |
| Cmax, mcg/mL | 1.3 [0.2, 3.9] | 1.9 [0.2, 4.3] | 1.0 [0.03, 2.6] | |
| AUC0-t, mcg-hr/mL | 16.2 [1.1, 69.9] | 40.1 [11.1, 78.9] | 9.5 [0.2, 51.6] | |
| CSF/Plasma Ratio | N | 11 | 12 | 9 |
| Cmax | 1200 [305, 4530] | 809 [202, 9370] | 1320 [541, 51200] | |
| AUC0-t | 393 [115, 1910] | 340 [126, 1780] | 1330 [167, 38900] | |
| 1 Tmax expressed as time since start of ~4.5 hour infusion. 2 Vss, CL, and t1/2 were not estimated due to insufficient plasma pharmacokinetic data |
||||
The estimated CSF volume of distribution of cerliponase alfa following intraventricular infusion of 300 mg of BRINEURA (median Vss = 245 mL) exceeds the typical CSF volume (100 mL).
Pediatric CLN2 patients ages 1 to < 2 years (n=2) and 2 to < 3 years (n=6) were administered cerliponase alfa according to the recommended dosing regimen based on age for up to 144 weeks. CSF exposure with 300 mg cerliponase alfa was within the range characterized to be safe and effective in pivotal Trial 1.
Plasma exposure in younger patients trended higher than the range characterized in the pivotal study. The pharmacokinetic parameters summarized by age at time of visit and dose are shown in Table 5.
Table 5: Pharmacokinetic Parameters of Cerliponase Alfa by Age at Visit and Dose Following Intraventricular Infusion of BRINEURA Every Two Weeks in Pediatric Patients < 3 years
| Age at Visit | Dose (mg) | Parameter | Median [Min, Max] | |
| 1 to < 2 years | 200 | CSF | N | 3 |
| Cmax, mcg/mL | 511 [163, 987] | |||
| AUC0-t, mcg-hr/mL | 2720 [1100, 5050] |
|||
| Plasma | N | 2 | ||
| Cmax, mcg/mL | 10.4 [9.46, 11.3] | |||
| AUC0-t, mcg-hr/mL | 91.8 [72.7, 111] | |||
| 300 | CSF | N | 2 | |
| Cmax, mcg/mL | 566 [496, 636] | |||
| AUC0-t, mcg-hr/mL | 8030 [8030, 8030]1 |
|||
| Plasma | N | 2 | ||
| Cmax, mcg/mL | 14.1 [11.2, 17.0] | |||
| AUC0-t, mcg-hr/mL | 145 [82.7, 206] | |||
| 2 to < 3 years | 300 | CSF | N | 6 |
| Cmax, mcg/mL | 896 [508, 1790] | |||
| AUC0-t, mcg-hr/mL | 4100 [2380, 6720]2 |
|||
| Plasma | N | 6 | ||
| Cmax, mcg/mL | 14.9 [9.08, 35.3] | |||
| AUC0-t, mcg-hr/mL | 163 [91.5, 320] | |||
| 1 N=1 due to less than 3 evaluable datapoints for determination of AUC0-t 2 N=5 due to less than 3 evaluable datapoints for determination of AUC0-t |
||||
Cerliponase alfa is a protein and is expected to be degraded through peptide hydrolysis.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies including cerliponase alfa.
In Trials 1 and 2 [see Clinical Studies], 19 of 24 (79%) and 10 of 24 (42%) patients treated with BRINEURA developed anti-drug antibodies (ADAs) in serum and CSF, respectively. Drug-specific neutralizing antibodies (NAb) capable of inhibiting receptor-mediated cellular uptake of cerliponase alfa were detected in the CSF of 3 of 24 (13%) patients at a single visit and were undetectable in all other CSF samples tested in ADA positive patients. In Trial 3 [see Clinical Studies], 14 of 14 (100%) and 3 of 14 (21%, all of the 3 patients were < 3 years of age) patients treated with BRINEURA developed ADAs in serum and CSF, respectively. NAb responses were not detected in the CSF of any ADA positive patients. Overall, patients younger than 3 years of age had higher ADA titers compared to patients 3 years of age and older.
In Trials 1 and 2, patients who experienced moderate to severe hypersensitivity adverse reactions were tested for drug-specific IgE and found to be negative. No association was found between serum ADA titers and incidence or severity of hypersensitivity. In Trial 3, hypersensitivity occurred in higher percentage in BRINEURA-treated patients < 3 years of age at baseline (amongst these patients, one patient experienced anaphylaxis), and higher ADA titers were also observed in this age group compared to patients ≥ 3 years of age at baseline. There was no identified clinically significant effect of ADA on pharmacokinetics or efficacy of BRINEURA. There is insufficient information to characterize the effects of ADA on safety.
The efficacy of BRINEURA was assessed over 96 weeks in a non-randomized single-arm dose escalation clinical study with extension in symptomatic pediatric patients with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, confirmed by TPP1 deficiency. BRINEURA-treated patients were compared to untreated patients from a natural history cohort. The Motor domain of a CLN2 Clinical Rating Scale was used to assess disease progression. Scores ranged from 3 (grossly normal) to 0 (profoundly impaired) with unit decrements representing milestone events in the loss of motor function (ability to walk or crawl). Due to the inability to establish comparability for the CLN2 Language domain ratings between the clinical study with extension and the natural history cohort, efficacy of BRINEURA for the Language domain cannot be established.
Twenty-four patients, aged 3 to 8 years were enrolled in the BRINEURA single-arm clinical study (Trial 1, NCT01907087). Sixty-three percent of patients were female and 37% were male. Ninety-six percent of patients were White and 4% were Asian; for ethnicity, 4% identified as Hispanic/Latino, 96% as non-Hispanic/Latino. One patient withdrew after week 1 due to inability to continue with study procedures; 23 patients were treated with BRINEURA 300 mg every other week by intraventricular infusion for 48 weeks, and continued treatment during the 240-week extension period, Trial 2 (NCT02485899), for a total duration of 288 weeks, plus a 24-week safety follow-up.
In the clinical study with extension, patients were assessed for decline in the Motor domain of the CLN2 Clinical Rating Scale at 48, 72 and 96 weeks. Decline was defined as having an unreversed (sustained) 2-category decline or an unreversed score of 0 in the Motor domain of the CLN2 Clinical Rating Scale. Patients’ responses to BRINEURA treatment were evaluated if at screening a combined Motor plus Language CLN2 score of less than 6 was recorded. Two patients with a combined Motor plus Language CLN2 score of 6 were excluded from the analyses; they maintained that score throughout the study period. The patient who terminated early was analyzed as having a decline at the time of termination. Data used in the analyses from the natural history cohort began at 36 months of age or greater and at the first time a Motor plus Language CLN2 score less than 6 was recorded.
Motor scores of the 22 BRINEURA-treated patients in the clinical study with extension were compared to scores of the independent natural history cohort that included 42 untreated patients who satisfied inclusion criteria for the clinical study. The results of logistic modeling with covariates (screening age, screening motor score, genotype: 0 key mutations (yes/no)), demonstrated the odds of BRINEURA-treated patients not having a decline by 96 weeks were 13 times the odds of natural history cohort patients not having a decline (Odds Ratio (95% CI): 13.1 (1.2, 146.9)).
In an unadjusted non-randomized comparison, of the 22 patients treated with BRINEURA and evaluated for efficacy at week 96, 21 (95%) did not decline, and only the patient who terminated early was deemed to have a decline in the Motor domain of the CLN2 Clinical Rating Scale. Results from the natural history cohort demonstrated progressive decline in motor function; of the 42 patients in the natural history cohort, 21 (50%) experienced an unreversed (sustained) 2-category decline or unreversed score of 0 in the Motor domain of the CLN2 Clinical Rating Scale over 96 weeks.
Given the non-randomized study design, a Cox Proportional Hazards Model adjusted for age, initial motor score, and genotype was used to evaluate time to unreversed 2-category decline or unreversed score of 0 in the Motor domain. This model showed a lesser decrease in motor function in the BRINEURA-treated patients when compared to the natural history cohort (see Figure 7).
Figure 7. Estimated Time to Unreversed (Sustained) 2-Category Decline or Unreversed Score of Zero in Motor Domain for Symptomatic Pediatric Patients in the BRINEURA Trials 1 and 2 at 96 Weeks and for Patients in a Natural History Cohort (Based on the Cox Proportional Hazards Model Adjusting for Covariates)
 |
| Shading represents 95% confidence intervals. Follow-up for the natural history cohort begins at 36 months of age or greater and at the first time a Motor plus Language CLN2 score less than 6 was recorded. The BRINEURA-treated population is the full population (N=24) minus two patients with baseline Motor plus Language CLN2 score = 6. Covariates: screening age, screening Motor score, genotype: 0 key mutations (yes/no). “Screening age” was defined in the natural history cohort as the age at the first time a Motor plus Language CLN2 score less than 6 was recorded, and no earlier than 36 months of age. The “screening Motor score” of the natural history cohort was defined as the Motor score at the screening age. Decline is defined as an unreversed (sustained) 2-category decline or unreversed score of 0 in the Motor domain of the CLN2 Clinical Rating Scale |
To further assess efficacy, the 22 patients from the BRINEURA clinical study with a baseline combined Motor plus Language CLN2 score less than 6 were matched to 42 patients in the natural history cohort. Patients were matched based on the following covariates: baseline age at time of screening within 3 months, genotype (0, 1, or 2 key mutations), and baseline Motor domain CLN2 score at time of screening.
Using the Motor domain of the CLN2 Clinical Rating Scale, decline was defined as having an unreversed 2-category decline or an unreversed score of 0. At 96 weeks, the matched analysis based on 17 pairs demonstrated fewer declines in the Motor domain for BRINEURA-treated patients compared to untreated patients in the natural history cohort (see Table 6).
Table 6: Proportion of Matched Symptomatic Pediatric Patients with CLN2 Disease without Decline1 in the BRINEURA Trials 1 and 2 and in the Natural History Cohort assessed at Weeks 48, 72, and 96
| Time Point/Period | Natural History Cohort (N=17) |
BRINEURA Treated (N=17) |
Difference | Odds Ratio3 |
| n (%) | n (%) | % (95% CI2) |
OR (95% CI) |
|
| Follow-up through Week 48 | 13 (76) | 16 (94) | 18% (-19, 51) |
4 (0.4, 200) |
| Follow-up through Week 72 | 11 (65) | 16 (94) | 29% (-7, 61) |
5.9 (0.7, 250) |
| Follow-up through Week 96 | 6 (35) | 16 (94) | 59% (24, 83) |
11 (1.6, 500) |
| 1 Decline is defined as an unreversed (sustained) 2-category decline or unreversed score of 0 in the Motor domain of the CLN2 Clinical Rating Scale. 2 Exact confidence interval for risk difference (Santner and Snell) 3 Based on McNemar’s Exact test Matched on baseline age at time of screening within 3 months, genotype (0, 1, or 2 key mutations), and baseline Motor domain CLN2 score at time of screening. The BRINEURA-treated population is based on the full population minus two patients with baseline Motor plus Language CLN2 score = 6. |
||||
Trial 3 (NCT02678689) was a Phase 2, open label clinical study designed to enroll symptomatic and presymptomatic CLN2 patients less than 18 years of age. The trial enrolled 14 patients ranging in age from 1 to 6 years at baseline, including 8 patients less than 3 years of age, the median age was 2.7 years. Patients received BRINEURA at the recommended dose every 2 weeks by intraventricular infusion for 144 weeks (1 patient withdrew to receive treatment commercially). Fifty-seven percent of patients were female and 43% were male. All patients were White; for ethnicity, 14% identified as Hispanic/Latino, 86% as non-Hispanic/Latino. The mean baseline CLN2 Motor score was 2.3 (standard deviation (SD) 0.83) with a range from 1 to 3.
Thirteen of the 14 BRINEURA treated patients were matched with up to 3 natural history comparators on the basis of age within 3 months, equal CLN2 Motor score, and genotype (0, 1, or 2 key mutations). None of the BRINEURA treated patients (N=14) had a 2-point decline or score of zero in the Motor scale by Week 169. Among the matched natural history comparators (N=31), 20 subjects (65%) had an unreversed 2-point decline or score of zero by last assessment.
The median time to an unreversed 2-point decline in Motor score or score of 0 was 133 weeks among the natural history comparators and was not reached by last assessment (Week 169) in patients treated with BRINEURA.
In patients below 3 years of age, none (0%) of the BRINEURA treated patients (N=8) had a 2-point decline or score of zero in the Motor score by Week 169. Among the 8 treated patients, 7 were matched to 18 untreated patients from the natural history cohort. Among the matched natural history comparators (N=18), 11 subjects (61%) had an unreversed 2-point decline or score of zero in the Motor score by last assessment. All seven of the treated patients below 3 years of age with a motor score of 3 at baseline remained at a motor score of 3 at the last measured timepoint, which represents grossly normal gait. In this population BRINEURA treated patients showed a delay in disease onset.
Advise patients and caregivers of the risk of device-related infections, including meningitis. Familiarize them with the signs and symptoms of these infections and instruct them to immediately contact their healthcare provider if an infection is suspected [see WARNINGS AND PRECAUTIONS].
Advise patients and caregivers that hypotension and/or bradycardia may occur during and following the infusion of BRINEURA. Instruct patients immediately to contact their healthcare provider if these reactions occur [see WARNINGS AND PRECAUTIONS].
